UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
NEW YORK, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Amicus Therapeutics, Inc. (NASDAQ:FOLD) securities during the period from September 15, 2015 through October 1, 2015, inclusive (the “Class Period”), of the important December 7, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Amicus Therapeutics investors under the federal securities laws.
To join the Amicus Therapeutics class action, go to the firm’s website at http://www.rosenlegal.com/cases-739.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that the United States Food and Drug Administration raised concerns about Amicus Therapeutics’ forthcoming new drug application for migalastat during their September 15, 2015 meeting. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2015. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-739.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
